GlassScriptPhysician profile
David D Hagaman
NPI 1235221656
$446,240.59
in general payments reported to CMS, 2019-2025
11 companies · $35K in 2025
The $35K reported for 2025 was more than what 94% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $78K · 2021: $25K · 2022: $68K · 2023: $40K · 2024: $73K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Travel and Lodging: $21K · Food and Beverage: $5,192 · Consulting Fee: $633 · Education: $23.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,274.65 |
| Travel and Lodging | $20,978.26 |
| Food and Beverage | $5,192.18 |
| Consulting Fee | $633.00 |
| Education | $23.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $250,603.76 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $180,446.57 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $11,266.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,716.18 | 2019-2025 | Fasenra |
| Jazz Pharmaceuticals INC. | $927.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.24 | 2024-2025 | Cuvitru, Hyqvia, Eohilia |
| Genentech, INC. | $276.33 | 2021-2024 | Xolair, Actemra |
| Harmony Biosciences LLC | $274.63 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $212.78 | 2023-2024 | Lumryz |
| Lilly USA, LLC | $118.53 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $65.95 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hagaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.